UCB (OTCMKTS:UCBJY) Stock Price Up 6.1% – Here’s Why

UCB SA (OTCMKTS:UCBJY)’s stock price was up 6.1% on Wednesday. The company traded as high as $121.16 and last traded at $121.16. 3,002 shares traded hands during trading, a decline of 93% from the average daily volume of 40,709 shares. The stock had previously closed at $114.20.

Analyst Ratings Changes

A number of brokerages recently weighed in on UCBJY. Zacks Research lowered shares of UCB from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 16th. Jefferies Financial Group raised UCB from a “moderate sell” rating to a “hold” rating in a research report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, UCB presently has a consensus rating of “Moderate Buy”.

UCB Stock Performance

The company’s 50 day moving average price is $121.05 and its two-hundred day moving average price is $134.86.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on developing and commercializing medicines for severe diseases in neurology and immunology. The company serves patients and healthcare professionals internationally, with operations and commercial activities spanning Europe, North America and other global markets.

UCB’s neurology portfolio includes medicines such as Vimpat (lacosamide) and Briviact (brivaracetam) for epilepsy, as well as Fintepla (fenfluramine) for certain seizure disorders.